75 related articles for article (PubMed ID: 20117847)
1. The missing link between clinical endpoints and drug targets in depression.
Della Pasqua O; Santen GW; Danhof M
Trends Pharmacol Sci; 2010 Apr; 31(4):144-52. PubMed ID: 20117847
[TBL] [Abstract][Full Text] [Related]
2. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.
Bech P; Tanghøj P; Andersen HF; Overø K
Psychopharmacology (Berl); 2002 Aug; 163(1):20-5. PubMed ID: 12185396
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model.
Santen G; Danhof M; Della Pasqua O
J Psychiatr Res; 2008 Oct; 42(14):1189-97. PubMed ID: 18353370
[TBL] [Abstract][Full Text] [Related]
4. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
Khan A; Schwartz K; Kolts RL; Ridgway D; Lineberry C
Biol Psychiatry; 2007 Jul; 62(1):65-71. PubMed ID: 17141744
[TBL] [Abstract][Full Text] [Related]
5. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.
Khan A; Brodhead AE; Kolts RL; Brown WA
J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562
[TBL] [Abstract][Full Text] [Related]
6. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
7. A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials.
Spielmans GI; McFall JP
J Nerv Ment Dis; 2006 Nov; 194(11):845-52. PubMed ID: 17102709
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.
Bremner JD
J Clin Psychiatry; 1995 Nov; 56(11):519-25. PubMed ID: 7592505
[TBL] [Abstract][Full Text] [Related]
9. Nefazodone: aspects of efficacy.
Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
[TBL] [Abstract][Full Text] [Related]
10. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury.
Ashman TA; Cantor JB; Gordon WA; Spielman L; Flanagan S; Ginsberg A; Engmann C; Egan M; Ambrose F; Greenwald B
Arch Phys Med Rehabil; 2009 May; 90(5):733-40. PubMed ID: 19406291
[TBL] [Abstract][Full Text] [Related]
12. Efficacy issues with antidepressants.
Fawcett J; Barkin RL
J Clin Psychiatry; 1997; 58 Suppl 6():32-9. PubMed ID: 9227671
[TBL] [Abstract][Full Text] [Related]
13. Placebo response and antidepressant clinical trial outcome.
Khan A; Detke M; Khan SR; Mallinckrodt C
J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
[TBL] [Abstract][Full Text] [Related]
14. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos.
Santor DA; Debrota D; Engelhardt N; Gelwicks S
Depress Anxiety; 2008; 25(9):774-86. PubMed ID: 17935212
[TBL] [Abstract][Full Text] [Related]
16. A scale for rating tricyclic response in major depression: the TRIM.
Nelson JC; Mazure CM
J Clin Psychopharmacol; 1990 Aug; 10(4):252-60. PubMed ID: 2286698
[TBL] [Abstract][Full Text] [Related]
17. Efficacy in long-term treatment of depression.
Montgomery SA
J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Increases in heart rate variability with successful treatment in patients with major depressive disorder.
Balogh S; Fitzpatrick DF; Hendricks SE; Paige SR
Psychopharmacol Bull; 1993; 29(2):201-6. PubMed ID: 8290666
[TBL] [Abstract][Full Text] [Related]
20. The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice.
Shajahan P; Taylor M
J Psychopharmacol; 2010 Apr; 24(4):565-72. PubMed ID: 19164493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
